Niowave and Ratio Partner to Advance Actinium-225 Supply
LANSING, Mich. and BOSTON, Mass., June 16, 2026 Niowave, Inc. and Ratio Therapeutics Inc. have entered into a strategic...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LANSING, Mich. and BOSTON, Mass., June 16, 2026 Niowave, Inc. and Ratio Therapeutics Inc. have entered into a strategic...
Dublin, Ohio, USA – April 1, 2026 In a significant advancement for the rapidly evolving field of targeted cancer...
CAMBRIDGE, England & BOSTON — December 16, 2025 — Bicycle Therapeutics plc, a clinical-stage pharmaceutical company pioneering bicyclic peptide–based...
BARCELONA, Spain, Oct. 8, 2025 — During the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM...
